OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Summary by AI BETAClose X

OKYO Pharma is advancing its lead drug candidate, urcosimod, for neuropathic corneal pain (NCP) following promising Phase 2 trial results where 75% of per-protocol patients receiving 0.05% urcosimod experienced an over 80% reduction in pain after 12 weeks. The company plans to initiate a multiple-ascending-dose clinical trial enrolling approximately 100 NCP patients across multiple U.S. sites. This randomized, placebo-controlled, double-masked trial aims to identify the optimal registration dose for future Phase 3 trials. OKYO anticipates topline data from this trial in 2026 and is progressing towards a meeting with the FDA to discuss requirements for an approvable drug.

Disclaimer*

UK 100

Latest directors dealings